Introduction 27 Multidrug-resistant tuberculosis (MDR-TB), caused by Mycobacterium tuberculosis complex (MTBC) 28 strains that are resistant to the first-line drugs isoniazid and rifampicin, represent a threat to global TB 29 control. Barely 20% of the estimated annual 480,000 new MDR-TB patients have access to adequate 30 second-line treatment regimens. The majority of undiagnosed or ineffectively treated MDR-TB patients 31 continue to transmit their infection and suffer high mortality (1) . 32 Based on early observations that the acquisition of drug resistance could lead to reduced bacterial fitness 33 (2) it was hypothesized that drug-resistant MTBC-strains had a reduced capacity to transmit, and would not 34 widely disseminate in the general population (3-7). This optimistic scenario has been invalidated by the 35 now abundant evidence for transmission of MDR and extensively drug-resistant MTBC-strains (XDR-TB; 36 MDR-TB additionally resistant to at least one fluoroquinolone and one aminoglycoside) in healthcare and 37 community settings (3, 8-11). In former Soviet Union countries, which experience the highest MDR-TB 38 rates worldwide, the expansion of drug-resistant MTBC-clones is thought be promoted by interrupted drug 39 supplies, inadequate implementation of regimens, lack of infection control and erratic treatment in prison 40 settings (12, 13) . Continued transmission is thought to be aided by the co-selection of mutations in the 41 bacterial population that compensate for a fitness cost (e.g. growth deficit) associated particularly with the 42 acquisition of rifampicin resistance mediating mutations (3, 7-11). The compensatory mechanism for 43 rifampicin resistant MTBC strains is proposed to be associated with structural changes in the RNA- 44 polymerase subunits RpoA, RpoB, and RpoC that increase transcriptional activity and as a consequence 45 enhance the growth rate (11). However, the impact of these bacterial genetic factors on the epidemiological 46 success of MDR-MTBC strains and implications for current and upcoming MDR-TB treatment strategies 47 remain unexplored. 48 We utilized whole genome sequencing (WGS) to retrace the longitudinal transmission and evolution of respectively), but increased to 76% in 2005-06 (P < 0.01). Over the same time periods, the proportions of 79 other strain types remained stable or decreased (Appendix Figure S2 ). 80 We then sized transmission networks (measured by transmission indexes, see methods) supposed to reflect 81 human-to-human transmission over the last ~10 years based on a maximum of 10 differentiating SNPs 82 between two strains. Transmission rates varied, even among closely related outbreak strains (Fig. 1) . 83 Beijing-CAO-strains formed particularly large transmission networks (>50 strains/patients; Fig. 1 ); 96.0% 84 (166/173) of all Beijing-CAO strains were associated with recent transmission (i.e. transmission index ≥1), 85 versus 48.4% (31/64) of non-CAO Beijing strains (P<0.0001) and 57.5% (23/40) of non-Beijing strains 86 (P<0.0001) (additional data). In addition the large CAO transmission network exhibited higher levels of 87 drug resistance relative to non-Beijing strains, as reflected by the larger number of drugs for which 88 phenotypic (P=0.0079) and genotypic drug resistance (P=0.0048) was detected Appendix Figure S3 ). 89 Evolutionary history of CAO strains in Karakalpakstan 90 In order to gain more detailed insights into the emergence of resistance mutations in the evolutionary history 91 of the CAO clade, we sought to employ a Bayesian phylogenetic analysis for a temporal calibration of the 92 CAO phylogeny and an estimation of the mutation rate. Using an extended collection of more diverse CAO 93 strains (n=220) from different settings (see methods) we initially compensated for the restricted sampling 94 time frame of the Karakalpakstan dataset (2001) (2002) (2003) (2004) (2005) (2006) . A linear regression analysis showed correlation 95 between sampling year and root-to-tip distance and a moderate temporal signal (P=0.00039, R 2 = 5.2%, 96 Appendix Figure S4 ), allowing for further estimation of CAO mutation rates and evaluation of molecular 97 clock models using Bayesian statistics. Based on the marginal L estimates collected by path sampling, we 98 found a strict molecular clock with tip dates to be most appropriate (Appendix Table S2 ). Mutation rate 99 estimates (under a relaxed clock model) ranged on average from 0.88 to 0.96 x 10 -7 substitutions per site 100 per year (s/s/y), depending on the demographic model, in favor for the Bayesian skyline model with 101 mutation rate of 0.94 x 10 -7 (s/s/y) (95% HPD 0.72-1.15 x 10 -7 (s/s/y)) (Appendix Table S2 ). 102 We then employed the Bayesian skyline model with a strict molecular clock set to 0.94 x 10 -7 (s/s/y) 103 specifically for the CAO clade from Karakalpakstan (n=173). We determined that the most recent common resistance to as many as eight different anti-TB drugs. Of note, only a single strain was identified as 120 harboring a gyrA mutation (A90V), associated to fluoroquinolone resistance (additional data 125 Overall, 62.1% (172/277) of all MDR-MTBC strains carried putative compensatory mutations (11, 13) in 126 rpoA (n=7), rpoC (n=126) and rpoB (n=43) (additional data). These mutations were almost completely 127 mutually exclusive, as only 4/172 strains harbored variants in more than one RNA polymerase-encoding 128 gene. While mutations in rpoA and rpoB were equally distributed between Beijing-CAO strains and other 129 non-outbreak Beijing strains, CAO-strains had more rpoC variants (56% vs 28%, P=0.003) (Appendix Table S3 ). The mean number of resistance mutations was higher among strains carrying compensatory 131 mutations ( Fig. 3A ), 4.77 vs 3.35 mutations (two-sample t-test P=1.2x10 -10 ). Notably, strains with 132 compensatory mutations also showed larger transmission indexes than strains presenting no compensatory 133 mutation, 37.16 vs 9.22 (Welch two-sample t-test P<2.2x10 -16 ) ( Fig. 3B ). CAO-strains with compensatory 134 mutation also had more resistance-conferring mutations than CAO-strains lacking such mutation (ANOVA, 135 Tukey multiple comparisons of means P adj=0.0000012). There was no difference observed for the means 136 of resistance-conferring mutations amon non-CAO strains; compensatory mutation present vs. absent (P 137 adj= 0.1978623) ( Fig. 3C ). 138 Regression-based analyses of transmission success scores in the Beijing-CAO clade confirmed that the 139 presence of compensatory mutations was strongly associated with cluster sizes independent of the 140 accumulation of resistance mutations ( Fig. 4 ). This pattern was mostly observed for clusters initiated in the 141 late 1980s and the 1990s. Figure S5 ). 158 Similar to Karakalpakstan, MDR-MTBC strains from Samara with compensatory mutations also 159 accumulated more resistance-associated mutations (4.57 vs 2.30 mutations per genome; two-sample t-test 160 P<2.2x10 -16 ) and had higher transmission indexes (50.32 vs 0.46; Welch two-sample t-test P<2.2x10 -16 ) 161 compared to strains lacking compensatory mutations (Appendix Figure S6 ). 162 The impact of resistance conferring and compensatory mutations on the transmission success score in 163 Beijing-A clade from Samara (Appendix Figure S7 European/Russian W148 (13, 22)) were identified in Karakalpakstan, suggesting that the MDR-TB 180 epidemic in this world region is driven by few outbreak clades. During the three last decades, these strains 181 gradually accumulated resistance to multiple anti-TB drugs that largely escaped phenotypic and molecular diagnostics, and reduce treatment options to a restricted set of drugs that often cause severe side effects. In 183 addition, our results suggest that compensatory mutations (in RNA-polymerase subunit coding genes) that 184 are proposed to ameliorate growth deficits in rifampicin resistant strains in vitro are also crucial in a global 185 epidemiological context allowing MDR and pre-XDR strains to form and maintain large transmission 186 networks. The predominance of these strain networks, seen in two distant geographic regions of the former 187 Soviet Union clearly limit the use of standardized MDR-TB therapies, e.g. the newly WHO endorsed short 188 MDR-TB regimen, in these settings. A particular concern is the high prevalence of mutations conferring resistance to second-line drugs currently Importantly, from the large spectrum of resistance detected among dominating strains in this study, it can 231 be predicted that standardized therapies, including the newly WHO endorsed short MDR-TB regimen in 232 Uzbekistan, are/will be largely ineffective for many patients in Samara and Karakalpakstan, and likely 233 elsewhere in Eurasia. In order to successfully control the worldwide MDR-TB epidemics, universal access 234 to rapid and comprehensive drug susceptibility testing, best supported by more advanced technologies, will 235 be crucial for guiding individualized treatment with existing and new/repurposed TB drugs and to maximize 236 chances of cure and prevention of further resistance acquisition. Table S1 ). (20) toolkits with regard to base quality re-calibration and alignment corrections for possible PCR artefact. 267 We considered variants that were covered by a minimum of 4 reads in both forward and reverse orientation, 268 4 reads calling the allele with at least a phred score of 20, and 75% allele frequency. In the combined 269 datasets, we allowed a maximum of 5% of all samples to fail the above mentioned threshold criteria in Mutations (small deletions and SNPs) in 34 resistance associated target regions (comprising 28 genes) were 286 considered for a molecular resistance prediction to 13 first-and second-line drugs (additional data). 287 Mutations in genes coding for the RNA-Polymerase subunits rpoA, rpoB (excluding resistance mediating 288 mutations), and rpoC were reported as putative fitness compensating (e.g. in vitro growth enhancing) 289 variants for rifampicin resistant strains. A detailed overview of all mutations considered as genotypic 290 resistance marker is given as additional data. Mutations that were not clearly linked to phenotypic drug 291 resistance were reported as genotypic non wild type and were not considered as genotypic resistance 292 markers. When no mutation (or synonymous, silent mutations) was detected in any of the defined drug 293 relevant target regions the isolate was considered to be phenotypically susceptible.
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294
Phylogenetic inference (maximum likelihood) 295 We used jModelTest v2.1 and Akaike and Bayesian Information Criterion (AIC and BIC) to find an 296 appropriate substitution model for phylogenetic reconstructions based on the concatenated sequence 297 alignments (Appendix Table S5 ). Maximum likelihood trees were calculated with FastTree 2.1.9 (double 298 precision for short branch lengths) (25) using a general time reversible (GTR) nucleotide substitution model 299 (best model according to AIC and second best model according to BIC), 1,000 resamplings and Gamma20 300 likelihood optimization to account for evolutionary rate heterogeneity among sites. The consensus tree was 301 rooted with the "midpoint root" option in FigTree and nodes were arranged in increasing order. 302 Polymorphisms considered as drug resistance marker (see above) and putative compensatory variants were 303 analyzed individually and mapped on the phylogenetic tree to define resistance patterns of identified 339 We used multiple linear regression to examine the respective contributions of antimicrobial resistance and 340 putative fitness cost-compensating mutations to the transmission success of tuberculosis. To take 341 transmission duration into account, we computed, for each isolate and each period length T in years (from Additional data: 705 34 Resistance targets (in 28 genes) and molecular markers considered as resistance predictor. 706 Phylogenetic variants in 34 resistance associated target genes. 707 DST phenotypes and polymorphisms in resistance and compensatory genes found in 705 MDR-MTBC 708 strains from Karakalpakstan, Uzbekistan and Samara, Russia and 19 CAO-Beijing strains from Germany. 709 Genotypic classification, transmission indexes, Accession numbers. 710 38 Central Asian outbreak (CAO) specific SNPs with annotations.
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